$VKTX One thing I find particularly interesting in Viking’s October presentation is the “Partnering discussions ongoing” for VK2809 and VK0214. Could this also be a strategic move to put some pressure on Big Pharma? If a potential buyer wants the entire Viking package, including all its assets, perhaps now is the time to make a serious offer before Viking signs separate partnerships. And if a buyout doesn’t happen? Viking could potentially receive significant upfront payments and future milestones from partnering those two programs, giving the company even more financial strength to focus entirely on its obesity pipeline, especially VK2735. I see a potentially bullish strategy here. Viking is creating options, strengthening its negotiating position, and making it clear that it doesn’t have to sell cheap. Just my speculation, but I like the position Viking is putting itself in. A major buyout or an even stronger independent Viking. Both could create substantial shareholder value!